Gut metagenomes in rCDI treated with RBX2660 or placebo
407 fecal samples from adult patients with recurrent C. difficile infection in a randomized, double-blind, placebo-controlled trial of the microbiota-based drug RBX2660 (one or two doses) versus placebo, administered via enema. machine-written summary
407 samples · 407 runs · Age unknown · 2020 · 1.49 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ○ Sequence archive | records read; no usable sample values |
| ○ Abstract / description | read; no usable statement |
| ✓ Full text | 1,221 sample values (collection date, health condition, health condition detail) · PMC7457799 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet · share metadata |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Faecal microbiota transplantation design randomized_controlled_trial · population gi_infection_or_diarrhoea · RBX2660 microbiota suspension vs placebo for recurrent C. difficile
“placebo-controlled clinical trial” — abstract:32862830 (study level; per-sample arms are in the intervention column below)
longitudinal — not resolved
Schedule stated by the source: “before and after administration of study drug (RBX2660 or placebo)” (time origin: intervention_start).
No Sandpiper profile for this project's samples yet.
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 407 | 100% | ||||
| country | 0 | 0% | ||||
| health_condition | 407 | 100% | 407 | |||
| subject_id | 0 | 0% | ||||
| collection_date | 407 | 100% | 407 | |||
| health_condition_detail | 407 | 100% | 407 |
- Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial. 2020 PMID 32862830 PMC7457799 own_data
Archive description
In this study, we explored the effect of a microbiota-based drug RBX2660, a suspension of healthy donor microbiota, on the gut microbiome and resistome of recipients treated for rCDI. rCDI patients received either a placebo (control group), one dose, or two doses of RBX2660. We demonstrate considerable shifts of taxonomic and resistome structures in placebo patients by RBX2660.
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of age unknown by sonnet_x2 with confidence 0.75. Assay shotgun_dna.
- host study.title · “fecal specimens from the patients”
- body site study.title · “fecal specimens from the patients”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN14121638 | collection_date | 2014-12/2015-11 | R3 | 0.70 | paper.fulltext.methods | 10 December 2014 through 13 November 2015 |
| SAMN14121638 | health_condition | gi_infection_or_diarrhoea | R3 | 0.70 | paper.fulltext.methods | Subjects were adults with recurrent CDI |
| SAMN14121638 | health_condition_detail | recurrent Clostridioides difficile infection (rCDI) | R3 | 0.70 | paper.fulltext.methods | Subjects were adults with recurrent CDI |
Sequencing
407 runs over 407 samples · mean 1.80 Gbp per run (median 1.49 Gbp, total 733.87 Gbp; 407 runs with a base count) · layout PAIRED 407 · platform ILLUMINA 407 · models Illumina HiSeq 4000 (407) · 90% of runs with a Sandpiper profile · first public 2020-12-05
Authors (12)
Kwak S first · Choi J · Hink T · Reske KA · Blount K · Jones C · Bost MH · Sun X · Burnham CD · Dubberke ER · Dantas G · CDC Prevention Epicenter Program last
Help complete this project
2 of the 4 core fields are below 50% coverage: country, subject_id. Share metadata
Downloads
PRJNA606075.csv.gz (9.9 KB) · parquet (83.8 KB) — all 407 samples, every field with route and confidence · PRJNA606075_determinations.csv.gz (5.4 KB) — 1,221 evidence rows